Corporate Banner
Satellite Banner
Technology Networks Header
Friday, August 22, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
  Videos

Return

Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer
SelectBio

The Aethlon HemopurifierĀ® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance. In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Test Reliably Detects Inherited Immune Deficiency in Newborns
NIH-supported study suggests that early diagnosis of severe combined immunodeficiency leads to high survival rates.
500 Million Year Reset for the Immune System
A single factor can reset the immune system of mice to a state likely similar to what it was 500 million years ago, when the first vertebrates emerged.
Sequencing Identifies Gene Variant Responsible for Lupus
Research demonstrates it is feasible to identify the individual causes of lupus in patients by using DNA sequencing, allowing doctors to target specific treatments to individual patients.
Test Reliably Detects Inherited Immune Deficiency in Newborns
NIH-supported study suggests that early diagnosis of severe combined immunodeficiency leads to high survival rates.
Immune Cells get Cancer-Fighting Boost From Nanomaterials
Yale researchers used bundled carbon nanotubes to incubate cytotoxic T cells.
Experimental Chikungunya Vaccine Induces Robust Antibody Response
Vaccine developed by NIH scientists performs well in early clinical trial.
Drugs Used to Treat Lung Disease Work With the Body Clock
Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective.
Making Cashews Safer for Those with Allergies
Scientists now develop a method to process cashews to make them safer to eat.
Early Treatment Benefits Infants with Severe Combined Immunodeficiency
NIH-funded study identifies factors contributing to successful stem cell transplants.
NIH Scientists Identify Gene Linked to Fatal Inflammatory Disease in Children
Repurposed drugs may offer first potential therapy.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv